Most Common Neuropathy in Diabetes
Distal symmetric polyneuropathy (DPN), also called distal symmetrical sensorimotor polyneuropathy, is the most common neuropathy in diabetes, affecting up to 50% of all diabetic patients with long disease duration 1, 2.
Clinical Pattern
DPN presents with a characteristic "glove and stocking" distribution of distal sensory or motor function loss 2. This nerve fiber length-dependent pattern means:
- Symptoms begin in the feet and progress proximally up the legs
- Later involvement may extend to hands and upper limbs
- Sensory symptoms predominate over motor involvement 3
The condition affects both type 1 and type 2 diabetes patients, though the prevalence increases with disease duration 1.
Key Clinical Features
Early manifestations include:
- Altered temperature sensation in the feet
- Impaired pain perception
- Progressive distal sensory loss
- Minimal motor involvement initially 3
Approximately 30-50% of patients with DPN develop painful symptoms 2, 1, though many will not have pain severe enough to warrant treatment. When pain occurs, it characteristically:
- Worsens at night, causing sleep disturbance
- Presents as burning, electrical shock-like, or lancinating sensations
- May include allodynia (pain from normally non-painful stimuli like bedclothes)
- Can be described as "walking barefoot on marbles" or "hot sand" 1
Other Neuropathy Patterns (Less Common)
While DPN is by far the most prevalent, diabetes can cause other neuropathy patterns 2:
- Autonomic neuropathy (frequently accompanies DPN)
- Focal neuropathies and mononeuropathies
- Radiculo-plexopathies
- Entrapment neuropathies (carpal tunnel syndrome, ulnar neuropathy)
However, chronic DPN remains the commonest of all diabetic neuropathies 1.
Clinical Significance
DPN carries substantial morbidity and mortality risk 2. It serves as a major risk factor for:
- Diabetic foot ulceration
- Charcot neuropathic osteoarthropathy
- Lower limb amputation
- Falls and fractures (particularly in elderly patients) 4
The high prevalence even in newly diagnosed type 2 diabetes patients (34% in one recent study) 5 underscores the importance of early screening, as many patients may have had undiagnosed diabetes for years before clinical presentation.